The BioInsights Podcast
The BioInsights Podcast: discussing the challenges of translating novel biologics from bench to clinic to market.
Episodes
49 episodes
Spatial mapping: shaping the future of I-O diagnostics and treatment
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with Banafshé Larijani, Director of the Centre for Therapeutic Innovation, University of Bath, about the development and application of a novel spatial ...
•
Season 3
•
Episode 11
•
38:44
Pioneering quality control in biomanufacturing of cell and gene therapies
Lauren Coyle, Commissioning Editor, speaks with Dhruv Sareen, Executive Director at Cedars-Sinai Biomanufacturing Center, and Johnathan Rodriguez, Quality Control Manager at Cedars-Sinai Biomanufacturing Center, about the r...
•
Season 3
•
Episode 10
•
28:08
Preparing for tomorrow’s cell and gene therapies today: lessons from 30 years in the field
For the first time in history, cell and gene therapy products are reaching the market in waves rather than in one’s and two’s, creating unprecedented challenges for pharma/biotech and healthcare sector stakeholders alike. David McCall, S...
•
Season 3
•
Episode 9
•
25:36
Insights into advanced therapies in the context of evolving funding and M&A environments
David McCall, Senior Editor, BioInsights, spoke to Lee Brown, Healthcare Sector Global Team Leader, Third Bridge Group, on Tuesday, February 6, 2024 to gain his insights into the fast-moving market landscape of advanced therapies....
•
Season 3
•
Episode 8
•
22:37
Fit for function: developing potency assays reflective of the in vivo environment
Translating the therapeutic promise of cell and gene therapies into clinical reality relies on robust potency assays. However, designing assays that accurately reflect the complex mechanisms of these therapies can feel like chasing a moving tar...
•
Season 3
•
Episode 7
•
28:20
Gene therapy is having a monumental year: how can the industry keep up with supply?
Lauren Coyle, Commissioning Editor, Cell & Gene Therapy Insights, talks with Suman Subramanian, Head of Commercial Operations, Catalent Cell and Gene Therapy, to discuss the major achievements in the gene therapy mark...
•
Season 3
•
Episode 6
•
23:36
A deep dive in to generative AI applications in I-O
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks with André Freitas, Senior Lecturer (University of Manchester) and Research Group Leader (Idiap Research Institute/National Biomarker Centre), about the...
•
Season 3
•
Episode 5
•
43:52
Developing novel radioimmunotherapy combinations for lung cancer treatment
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, speaks to Joe Chang, Clinical Thoracic Oncologist, MD Anderson Cancer Center, University of Texas, who discusses his team’s pioneering work in combining radiat...
•
Season 3
•
Episode 4
•
14:57
Focusing on the fundamentals: what do and don’t we know about mRNA delivery?
As excitement around the evolving field of mRNA continues to grow, there remain somefundamental questions to be answered. David McCall, Senior Editor, Nucleic Acid Insights, spoke with Monash University’s Colin Pouton...
•
Season 3
•
Episode 3
•
45:24
Navigating genomics and transcriptomics in the immuno-oncology space
Lauren Coyle, Commissioning Editor, Immuno-Oncology Insights, interviews Katie Campbell, Postdoctoral Fellow, Cancer Research Institute, about her current research on genomics, transcriptomics, and spatial profiling to address challenges in the...
•
Season 3
•
Episode 2
•
20:23
Avian influenza and the risk of pandemic
With the potential for avian influenza to transmit and spread amongst humans, an effective vaccine to increase pandemic preparedness is a global priority. Charlotte Barker, Editor, Vaccine Insights, speaks with Mathilde Richard, Principal Inves...
•
Season 3
•
Episode 1
•
23:38
Exploring the landscape of novel targets & pathways in immuno-oncology
Lauren Coyle, Editor, Immuno-Oncology Insights, speaks to Yvonne McGrath, Chief Scientific Officer, iTeos Therapeutics, about the current and emerging novel targets and pathways for the use of cancer therapy in the I-O fi...
•
Season 2
•
Episode 16
•
17:05
Multiomics integration: advancing pediatric cancer immunotherapy
Lauren Coyle, Editor, Immuno-Oncology Insights, speaks with Raoul Santiago, Clinical Investigator and Associate Professor of Pediatric Hematology and Oncology, University Hospital Center, Laval University, to discuss the role of m...
•
Season 2
•
Episode 15
•
19:37
Building with the patient in mind: designing a state-of-the-art facility for viral vector manufacturing
The cell and gene therapy space poses a number of unique challenges when it comes to facility design. In this episode, Róisin McGuigan, Editor, BioInsights, speaks to Yposkesi’s Louis-Marie De Montgrand and Morad El Gueddari
•
Season 2
•
Episode 14
•
28:44
Can AAV continue to deliver the promise of gene therapy?
In this episode, Charlotte Barker, Editor, BioInsights, will be discussing the future of AAV-based gene therapy manufacturing with Elie Hanania, VP of Process Development Viral Vector Technologies at Avid Bioservices, and Ratish Krishnan, Senio...
•
Season 2
•
Episode 13
•
21:37
Expanding the potential of in vivo cell therapy with tLNP-RNAs (targeted lipid nanoparticle-RNA)
The application of lipid nanoparticles (LNPs) as a non- viral delivery system for advanced therapies, in conjunction with RNA-based medicines, is set to revolutionize the field. In this episode, David McCall, Senior Editor, BioInsights, s...
•
Season 2
•
Episode 12
•
20:04
Investing long-term in the cell & gene therapies of the future
David McCall, Senior Editor, BioInsights, speaks to Geeta Vemuri, Founder and Managing Partner, Agent Capital, about her VC company's portfolio of advanced therapy investments, and the keys to obtaining funding in a difficult environment. (From...
•
Season 2
•
Episode 11
•
15:25
Happy medium: considerations in scaling cell culture media strategies
While attractive from an initial cost perspective, performing early development in a cell culture substrate that does not match a therapy’s final manufacturing platform can have critical implications on development timelines. In this podcast,&n...
•
Season 2
•
Episode 10
•
19:11
Applying multiomics to novel target discovery in immuno-oncology
In this episode, Róisin McGuigan, Editor, Immuno-Oncology Insights, speaks with Eran Ophir, Chief Scientific Officer, Compugen, and Yaron Turpaz, Senior Vice President and Senior Advisor, Data and Informatics Solutions, Compugen, about...
•
Season 2
•
Episode 9
•
18:42
Modernizing cell therapy manufacturing to reduce vein-to-vein times
Charlotte Barker (Editor, BioInsights) speaks with Curate Biosciences’ CEO David Backer and CTO Tony Ward about the need for CAR-T cell therapy manufacturing to evolve, and how a new cell separation technique could boost efficiency.
•
Season 2
•
Episode 8
•
23:49
Inducing innate immune responses with particulate adjuvants
Charlotte Barker, Editor, Vaccine Insights, speaks with Ed Lavelle, Professor, Trinity College Dublin, about our growing understanding of adjuvant mechanisms, his work on developing mucosal vaccines, and why size matters for nanopartic...
•
Season 2
•
Episode 7
•
13:38
Navigating the complexities of biodistribution, transgene expression & vector shedding in gene therapy development
In this episode Róisin McGuigan (Editor, BioInsights) speaks to Paul Byrne (Senior Director, Genomics, ProtaGene) about the evolution of the gene therapy field, with a specific focus on the complexities posed by biodistribution, vector shedding...
•
Season 2
•
Episode 6
•
31:06
Non-viral methods for ex vivo cell & gene therapy: is the future non-viral?
Non-viral methods for ex vivo cell & gene therapy: is the future non-viral? In this episode, Valeria Annibaldi and Andrea Toell discuss the types and benefits of non-viral methods for ex vivo cell and gene therapy in addit...
•
Season 2
•
Episode 5
•
21:37
Solving challenges in cell therapy clinical trials & effectively delivering complex studies in advanced therapeutics
Cell therapy clinical trials pose a variety of complex challenges. Logistics with cell harvesting, manufacturing, shipments back to sites, patient safety, changing standard-of-care treatments, and patient enrolment due to competing trials can a...
•
Season 2
•
Episode 4
•
25:00
Shear ignorance? Think again: breaking the perception of shear within viral vector manufacturing
The tangential flow filtration (TFF) unit operation in viral vector manufacturing is a critical step on the path to commercialization. In this episode, Merck viral vector experts Ratish Krishnan and Akshat Gupta discuss best practices – and com...
•
Season 2
•
Episode 3
•
18:05